Oxford BioTherapeutics And Boehringer Ingelheim Enter Collaboration To Discover Novel Antibody Targets In Cancer

Date: May-01-2013Oxford BioTherapeutics (OBT) and Boehringer Ingelheim(BI) have announced a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP(R) discovery platform.

Under the collaboration OBT will validate certain targets it has discovered that are
compatible with targeting by various antibody drug formats across a range of cancer
indications. Following completion of these activities, BI will have the exclusive right to
develop and commercialize antibody products for selected programs.

OBT will receive an undisclosed upfront payment and FTE funding for its activities
under the collaboration, and will be eligible for certain milestone payments upon the
achievement of specified discovery, development and commercialization milestones, as well
as royalties on sales of any resulting products.

Christian Rohlff, CEO of OBT, commented: "Selecting the right target is fundamental
for the successful development of a first in class antibody product drug and we are
delighted to collaborate with a company of the calibre of BI in this exciting area of
cancer antibody development."
Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.